On August 2, 2022 Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, reported that management will participate in two upcoming investor conferences (Press release, Harpoon Therapeutics, AUG 2, 2022, View Source [SID1234617293]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A panel discussion, "For Your IOnly – Progress, Challenges in Immuno-Oncology" at the Wedbush PacGrow Healthcare Conference (hybrid) at 2:20 p.m. ET (11:20 a.m. PT) on Tuesday, August 9, 2022; and
A corporate presentation at the Canaccord Genuity 42nd Annual Growth Conference in Boston, at 12 p.m. ET (9 a.m. PT) on Wednesday, August 10, 2022.
A live audio webcast of these events will be available in the Investors section of the Harpoon Therapeutics website at www.harpoontx.com with an archived replay available following each event.